IBIO Share Price

Open 0.42 Change Price %
High 0.43 1 Day 0.01 2.44
Low 0.40 1 Week -0.01 -2.33
Close 0.42 1 Month -0.06 -12.50
Volume 138929 1 Year -0.14 -25.00
52 Week High 0.80
52 Week Low 0.34
IBIO Important Levels
Resistance 2 0.45
Resistance 1 0.44
Pivot 0.42
Support 1 0.40
Support 2 0.39
AMEX USA Most Active Stocks
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
NAK 1.75 -8.38%
NAK 1.75 -8.38%
RBY 0.03 -70.00%
PBTH 8.23 0.37%
NGD 3.80 -2.81%
NGD 3.80 -2.81%
SYRG 9.82 -0.30%
More..
AMEX USA Top Gainers Stocks
GGR 0.02 100.00%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
CPHI 0.29 52.63%
IGC 0.33 37.50%
IGC 0.33 37.50%
IGC 0.33 37.50%
MBA 0.20 25.00%
More..
AMEX USA Top Losers Stocks
RBY 0.03 -70.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
QBC 0.20 -33.33%
ATL 0.06 -25.00%
ATL 0.06 -25.00%
SNT 0.12 -20.00%
INV 0.14 -17.65%
INV 0.14 -17.65%
More..

iBio, Inc. (AMEX: IBIO)

IBIO Technical Analysis 5
As on 9th Dec 2016 IBIO Share Price closed @ 0.42 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.59 & Strong Sell for SHORT-TERM with Stoploss of 0.49 we also expect STOCK to react on Following IMPORTANT LEVELS.
IBIO Target for December
1st Target up-side 0.53
2nd Target up-side 0.61
3rd Target up-side 0.68
1st Target down-side 0.31
2nd Target down-side 0.23
3rd Target down-side 0.16
IBIO Other Details
Segment EQ
Market Capital 43945728.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.ibioinc.com
IBIO Address
IBIO
9 Innovation Way
Suite 100
Newark, DE 19711
United States
Phone: 302-355-0650
Interactive Technical Analysis Chart iBio, Inc. ( IBIO AMEX USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on iBio, Inc.
IBIO Business Profile
iBio, Inc., a biotechnology company, focuses on the commercialization of its proprietary plant-based protein expression technologies in the United States and internationally. Its proprietary technologies include iBioLaunch, a transformative platform technology for the development and production of biologics; and iBioModulator, a technology platform that improves the potency and duration of the effect of prophylactic and therapeutic vaccines. The company’s product candidates include C1 Esterase Inhibitor, a preclinical stage plasma-derived protein; Alpha-Galactosidase, a preclinical orphan designation stage enzyme replacement; and Palivizumab, a preclinical stage monoclonal antibody for the therapeutic protein market. Its product candidates also comprise H1N1 Influenza and H5N1 Influenza viral disease vaccines that completed Phase I; Hookworm parasitic pathogen vaccine, which is in preclinical stage; and Human Papillomavirus therapeutic vaccine that is in preclinical stage. In addition, the company’s product candidates include Anthrax/Plague bacterial disease vaccine that is in preclinical stage; and Anthrax monoclonal antibody that is in preclinical stage for the Biodefense market. It has a collaboration agreement with Fraunhofer Center for Molecular Biology to perform research and development activities to develop the recombinant form of C1 esterase inhibitor; an alliance with GE Healthcare to commercialize its plant-based technologies for the manufacture of biopharmaceuticals and vaccines; a collaboration agreement granting FioCruz/Bio-Manguinhos a license to use its proprietary technology in connection with the development, manufacture, and commercialization of vaccine products; and a license and collaboration agreement enabling Caliber Biotherapeutics LLC to use its iBioLaunch platform in connection with the development of an undisclosed monoclonal antibody-based therapeutic protein for an oncology indication. The company is headquartered in Newark, Delaware.